Hikma Pharmaceuticals PLC HIK shares slipped 1.68% to £19.86 Monday, on what proved to be an all-around rough trading session ...

Hikma Pharmaceuticals PLC HIK shares shed 2.70% to £20.16 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.02% to ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...

Cisatracurium besylate injection has a market value of approximately $14 million in the 12 months ending January 2025, per ...

Health Canada approves Hikma Pharma’s Kloxxado nasal spray 8 mg for treatment of known or suspected opioid overdose: London Monday, March 24, 2025, 13:00 Hrs [IST] Hikma Pharmac ...

Hikma Pharmaceuticals (HKMPF) announces the approval of KLOXXADO Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected ...

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of ...

(RTTNews) - Hikma Pharmaceuticals (HIK) announced the approval of KLOXXADO Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected opioid overdose, as manifested by respiratory ...

LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ...